Search Results

Paraguay's Nuclear Power Generation Debate Heats Up: Regulator Supports Private Sector Participation

Paraguay's Radiation and Nuclear Regulatory Authority (ARRN) has welcomed the open attitude shown by the National Electricity Administration (ANDE), stating that allowing or encouraging private sector participation in nuclear power generation projects would bring new discussion space to the country's energy mix. This stance indicates that nuclear energy is no longer just a long-term technical vision but has begun to enter the public agenda of policy, investment, and regulatory coordination. Paraguay has long relied on hydropower resources, with major projects such as Itaipu and Yacyretá giving it an advantage in clean electricity. However, with domestic industrialization, growing electricity consumption, and changes in the regional energy market, sole reliance on hydropower also faces pressures from seasonality, hydrological conditions, and long-term demand...

2026-08-10

Putin Signs Decree Posthumously Awarding "Order of Courage" to Chief Engineer of Zaporizhzhia Nuclear Power Plant

Russian President Vladimir Putin recently signed a decree posthumously awarding the Order of Courage to Alexander Yakovlev, chief engineer of the Zaporizhzhia Nuclear Power Plant, who was killed in an attack, in recognition of his bravery demonstrated in the line of duty. According to previously released information, the Russian Foreign Ministry issued a statement on July 15 stating that a service vehicle of the Zaporizhzhia Nuclear Power Plant was attacked by a drone that day, and Yakovlev was killed in the attack. The statement said the attack posed a threat to the safe operation of the Zaporizhzhia Nuclear Power Plant. The Zaporizhzhia Nuclear Power Plant is one of the larger nuclear power facilities in Europe, and its operational safety has long drawn external attention...

2026-08-05

US FDA Approves Pluvicto Expanded Indication for Treatment of PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

On July 31, 2026, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer. This disease is commonly referred to as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on results from the Phase III PSMAddition trial. The study showed that compared with standard of care alone, namely ARPI combined with androgen deprivation therapy (ADT), Pluvicto plus standard of care reduced the risk of disease progression or death by...

2026-08-03